Generic Name and Formulations:
Amitriptyline HCl 10mg, 25mg, 50mg, 75mg, 100mg, 150mg; tabs.
Various generic manufacturers
Indications for Amitriptyline:
Depression especially endogenous.
Initially 75mg daily in divided doses or 50–100mg daily at bedtime; max 150mg daily. Elderly and adolescents: reduce dose.
During or within 14 days of MAOIs. Acute post MI.
History of seizures, urinary retention, glaucoma. Cardiovascular disease. Suicidal tendencies. Surgery. ECT. Psychosis. Hyperthyroidism. Liver dysfunction. Diabetes. Gradually reduce to lowest effective maintenance dose. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). May block guanethidine. Potentiates alcohol, barbiturates, other CNS depressants. Delirium with disulfiram, ethchlorvynol. Paralytic ileus with anticholinergics. Hyperpyrexia with anticholinergics, sympathomimetics. Monitor serum levels with CYP450 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature).
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, stroke, coma, confusion, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, increased perspiration, headache, photosensitivity, edema, blood dyscrasias, alopecia, libido changes, changes in blood sugar; women: breast enlargement, galactorrhea; men: testicular swelling, gynecomastia.
Formerly known under the brand name Elavil.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally